Cyclometalated iridium(III) complexes are of significant
importance
in the field of antitumor photodynamic therapy (PDT), whether they
exist as single molecules or are incorporated into nanomaterials.
Nevertheless, a comprehensive examination of the relationship between
their molecular structure and PDT effectiveness remains awaited. The
influencing factors of two-photon excited PDT can be anticipated to
be further multiplied, particularly in relation to intricate nonlinear
optical properties. At present, a comprehensive body of research on
this topic is lacking, and few discernible patterns have been identified.
In this study, through systematic structure regulation, the nitro-substituted
styryl group and 1-phenylisoquinoline ligand containing YQ2 was found to be the most potent infrared two-photon excitable photosensitizer
in a 4 × 3 combination library of cyclometalated Ir(III) complexes. YQ2 could enter cells via an energy-dependent and caveolae-mediated
pathway, bind specifically to mitochondria, produce 1O2 in response to 808 nm LPL irradiation, activate caspases,
and induce apoptosis. In vitro, YQ2 displayed a remarkable
phototherapy index for both malignant melanoma (>885) and non-small-cell
lung cancer (>1234) based on these functions and was minimally
deleterious
to human normal liver and kidney cells. In in vivo antitumor phototherapy, YQ2 inhibited tumor growth by an impressive 85% and could
be eliminated from the bodies of mice with a half-life as short as
43 h. This study has the potential to contribute significantly to
the development of phototherapeutic drugs that are extremely effective
in treating large, profoundly located solid tumors as well as the
understanding of the structure–activity relationship of Ir(III)-based
PSs in PDT.